Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
Harmony Biosciences trades at discounted valuations, but investors are weighing Wakix dependence, recent earnings misses and pipeline execution.
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
Harmony Biosciences is leveraging Wakix growth to expand its neuroscience pipeline, while advancing pitolisant programs and rare disease assets.
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.
Harmony Biosciences Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 145 | $5,425.91 | $5,402.7 | -$23.21 | -0.43% |
| BG Bart Gancher Intech Investment Management LLC | 16,892 | $570,528.48 | $629,395.92 | $58,867.44 | 10.32% |
 Bridgewater Associates LP Bridgewater Associates LP | 251,506 | $7.11M | $9.37M | $2.26M | 31.81% |
 Anthony Scaramucci SkyBridge Capital II LLC | 1.62M | $50.19M | $60.51M | $10.32M | 20.55% |
| YA Yinka Akinsola Blue Trust Inc. | 29 | $1,085.18 | $1,080.54 | -$4.64 | -0.43% |
Harmony Biosciences Holdings, Inc. (HRMY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Harmony Biosciences Holdings, Inc. ever had a stock split?
Harmony Biosciences Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey Dayno CEO | NASDAQ (NMS) Exchange | 413197104 CUSIP |
| US Country | 268 Employees | - Last Dividend | - Last Split | 19 Aug 2020 IPO Date |
Overview
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company dedicated to the development and commercialization of unique therapies for patients suffering from rare and other neurological diseases within the United States. Initially known as Harmony Biosciences II, Inc., the company underwent a name change to Harmony Biosciences Holdings, Inc. in February 2020. Founded in 2017, Harmony Biosciences has established its headquarters in Plymouth Meeting, Pennsylvania, signifying its commitment to addressing unmet medical needs in the neurology space through innovative research and therapeutic solutions.
Products and Services
- WAKIX (pitolisant)
- HBS-102
Harmony Biosciences offers WAKIX (pitolisant), which is a pioneering molecule known for its novel mechanism of action. It is specifically designed for the treatment of excessive daytime sleepiness in adult patients suffering from narcolepsy. This product marks a significant advancement in narcolepsy treatment, offering a new hope and improved quality of life for patients grappling with this chronic sleep disorder.
Another significant therapeutic solution in Harmony Biosciences' portfolio is HBS-102, which targets the melanin-concentrating hormone receptor 1 for MCH neurons. This product represents the company's ongoing commitment to exploring new pathways and mechanisms to address neurological disorders with unmet medical needs. While still under development, HBS-102 underscores Harmony Biosciences’ dedication to expanding its offerings and making impactful contributions to the field of neurology.
